Bioinformatics All biologists today are experiencing an increased need for bioinformatics/computational biology. This need is particularly acute for those carrying out high throughput screens or otherwise engaged in 'omic' biology. For this reason, program members uniformly see the need -for enhanced bioinformatics support. This might be housed within the current Biostatistics Core or within a center for cancer systems biology. vii. Value Added of the Center to the Program ? The center provides access to program cores at favorable rates (see table below). ? Many of our top scientific accomplishments (see I, iv above) were enabled by these cores. ? Collaborations that were encouraged and facilitated by the Center have developed into new P01 grant awards to the Program. Other collaborations brought new projects into existing P01 grants and contributed in substantive ways to their competitive renewal (see 9d iv above). ? The center provides Developmental """"""""seed grants"""""""" to jump-start meritorious projects. During the current funding period, two members of the program have received developmental awards. They are: Fisher0''- award # 03-22C-NN (new nodal) """"""""Role of melanin biosythetic intermediates in melanoma carcinogenesis"""""""" 2 years X $75K and CantleyBIDMC - award # 03-35G Molecular Imaging Initiative """"""""Image signaling transduction kinases"""""""" $34.5K Finally the center allows basic scientists to contribute more directly to the clinical facets of a comprehensive cancer center such as in drug discovery and clinical trials. For example, Dr. Stiles is providing metrics to Dr. Patrick Wen WH (Program in Neuro Oncology) for a clinical trial on Gleevec for patients with recurrent Glioblastoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-22
Application #
7917268
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
22
Fiscal Year
2009
Total Cost
$175,281
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90

Showing the most recent 10 out of 1493 publications